---
title: 'Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results
  from the US lymphoma CAR-T consortium'
date: '2023-12-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38051550/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231206170832&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: During the manufacturing period of autologous chimeric antigen receptor
  (CAR) T cell therapy, patients may experience a decline in their condition due to
  cancer progression. In this study, we investigated the impact of "bridging therapy"
  (BT) on the outcome of patients with relapsed/refractory large B cell lymphoma who
  received anti-lymphoma treatment between leukapheresis and axicabtagene ciloleucel
  (axi-cel) infusion. We conducted our analysis using data from the multicenter US
  Lymphoma CAR ...
disable_comments: true
---
During the manufacturing period of autologous chimeric antigen receptor (CAR) T cell therapy, patients may experience a decline in their condition due to cancer progression. In this study, we investigated the impact of "bridging therapy" (BT) on the outcome of patients with relapsed/refractory large B cell lymphoma who received anti-lymphoma treatment between leukapheresis and axicabtagene ciloleucel (axi-cel) infusion. We conducted our analysis using data from the multicenter US Lymphoma CAR ...